CoChat

YAP inhibits squamous transdifferentiation of Lkb1-deficient lung adenocarcinoma through ZEB2-dependent DNp63 repression

Open access
Gao, Yijun, Zhang, Wenjing, Han, Xiangkun, Li, Fuming, Wang, Xujun, Wang, Rui, Fang, Zhaoyuan, Tong, Xinyuan, Yao, Shun, Li, Fei, Feng, Yan, Sun, Yihua, Hou, Yingyong, Yang, Zhongzhou, Guan, Kunliang, Chen, Haiquan, Zhang, Lei, Ji, Hongbin · 2014 · Nature Communications
Cited by 123

The DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.

Abstract

Whether the Hippo pathway contributes to cell lineage transition under pathological conditions, especially tumorigenesis, remains largely unknown. Here we show that YAP, the major effector of the Hippo pathway, displays a distinct activation pattern in lung adenocarcinoma (ADC) and squamous cell carcinoma (SCC); YAP is initially activated by LKB1 loss in lung ADC, which upregulates ZEB2 expression and represses DNp63 transcription in a default manner. During transdifferentiation, YAP is inactivated, which in turn relieves ZEB2-mediated default repression of DNp63 and triggers squamous differentiation reprogramming. Disruption of the YAP barrier for phenotypic transition significantly accelerates squamous transdifferentiation, whereas constitutive YAP activation conversely inhibits this transition. More importantly, ectopic DNp63 expression rescues the inhibitory effect of YAP on squamous transdifferentiation. These findings have established YAP as an essential barrier for lung cancer cell fate conversion and provided a mechanism for regulating cancer plasticity, which might hold important implication for YAP-targeted therapies. Lung adenocarcinomas can convert to squamous cell carcinomas, which is associated with cancer progression and therapy resistance. Here, Gao et al. identify YAP as an essential barrier for this phenotypic conversion through ZEB2-mediated DNP63 repression.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/ncomms5629

Cites

10 of 10 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Research works printed but not linked: 39

  1. Edgar, B. A. From cell structure to transcription: Hippo forges a new path. Cell 124, 267–273 (2006). · DOI · Paper page
  2. Nolo, R., Morrison, C. M., Tao, C. Y., Zhang, X. W. & Halder, G. The bantam microRNA is a target of the hippo tumor-suppressor pathway. Curr. Biol. 16, 1895–1904 (2006). · DOI · Paper page
  3. Zhao, B., Lei, Q.-Y. & Guan, K.-L. The Hippo-YAP pathway: new connections between regulation of organ size and cancer. Curr. Opin. Cell Biol. 20, 638–646 (2008). · DOI · Paper page
  4. Nishioka, N. et al. The Hippo signaling pathway components Lats and Yap pattern Tead4 activity to distinguish mouse trophectoderm from inner cell mass. Dev. Cell 16, 398–410 (2009). · DOI · Paper page
  5. Leung, C. Y. & Zernicka-Goetz, M. Angiomotin prevents pluripotent lineage differentiation in mouse embryos via Hippo pathway-dependent and -independent mechanisms. Nat. Commun. 4, 2251 (2013). · DOI · Paper page
  6. Hiemer, S. E. & Varelas, X. Stem cell regulation by the Hippo pathway. Biochim. Biophys. Acta 1830, 2323–2334 (2013). · DOI
  7. Harvey, K. F., Zhang, X. & Thomas, D. M. The Hippo pathway and human cancer. Nat. Rev. Cancer 13, 246–257 (2013). · DOI · Paper page
  8. Steinhardt, A. A. et al. Expression of Yes-associated protein in common solid tumors. Hum. Pathol. 39, 1582–1589 (2008). · DOI · Paper page
  9. Wang, Y. et al. Overexpression of yes-associated protein contributes to progression and poor prognosis of non-small-cell lung cancer. Cancer Sci. 101, 1279–1285. · DOI · Paper page
  10. Overholtzer, M. et al. Transforming properties of YAP, a candidate oncogene on the chromosome 11q22 amplicon. Proc. Natl Acad. Sci. USA 103, 12405–12410 (2006). · DOI · Paper page
  11. Zhou, D. et al. Mst1 and Mst2 maintain hepatocyte quiescence and suppress hepatocellular carcinoma development through inactivation of the Yap1 oncogene. Cancer Cell 16, 425–438 (2009). · DOI · Paper page
  12. Han, X. et al. Transdifferentiation of lung adenocarcinoma in mice with Lkb1 deficiency to squamous cell carcinoma. Nat. Commun. 5, 3261 (2014). · DOI · Paper page
  13. Serrano, I., McDonald, P. C., Lock, F., Muller, W. J. & Dedhar, S. Inactivation of the Hippo tumour suppressor pathway by integrin-linked kinase. Nat. Commun. 4, 2976 (2013). · DOI · Paper page
  14. Sutherland, K. D. & Berns, A. Cell of origin of lung cancer. Mol. Oncol. 4, 397–403 (2010). · DOI · Paper page
  15. Meuwissen, R. & Berns, A. Mouse models for human lung cancer. Genes Dev. 19, 643–664 (2005). · DOI · Paper page
  16. Lau, A. N. et al. Tumor-propagating cells and Yap/Taz activity contribute to lung tumor progression and metastasis. EMBO J. 33, 468–481 (2014). · DOI · Paper page
  17. Xie, M. et al. Prognostic significance of TAZ expression in resected non-small cell lung cancer. J. Thorac. Oncol. 7, 799–807 (2012). · DOI
  18. Zhou, Z. et al. TAZ is a novel oncogene in non-small cell lung cancer. Oncogene 30, 2181–2186 (2011). · DOI · Paper page
  19. Zhao, B. et al. Cell detachment activates the Hippo pathway via cytoskeleton reorganization to induce anoikis. Genes Dev. 26, 54–68 (2012). · DOI · Paper page
  20. Vandewalle, C. et al. SIP1/ZEB2 induces EMT by repressing genes of different epithelial cell-cell junctions. Nucleic Acids Res. 33, 6566–6578 (2005). · DOI · Paper page
  21. Littlewood, T. D., Hancock, D. C., Danielian, P. S., Parker, M. G. & Evan, G. I. A modified oestrogen receptor ligand-binding domain as an improved switch for the regulation of heterologous proteins. Nucleic Acids Res. 23, 1686–1690 (1995). · DOI · Paper page
  22. Visvader, J. E. Cells of origin in cancer. Nature 469, 314–322 (2011). · DOI · Paper page
  23. Blanpain, C. Tracing the cellular origin of cancer. Nat. Cell Biol. 15, 126–134 (2013). · DOI · Paper page
  24. Wang, R. et al. Glioblastoma stem-like cells give rise to tumour endothelium. Nature 468, 829–833 (2010). · DOI · Paper page
  25. Ricci-Vitiani, L. et al. Tumour vascularization via endothelial differentiation of glioblastoma stem-like cells. Nature 468, 824–828 (2010). · DOI · Paper page
  26. Snyder, E. L. et al. Nkx2-1 represses a latent gastric differentiation program in lung adenocarcinoma. Mol. Cell 50, 185–199 (2013). · DOI · Paper page
  27. Shu, C. et al. Thymidylate synthase expression and molecular alterations in adenosquamous carcinoma of the lung. Mod. Pathol. 26, 239–246 (2013). · DOI
  28. Jia, X. L. & Chen, G. EGFR and KRAS mutations in Chinese patients with adenosquamous carcinoma of the lung. Lung Cancer 74, 396–400 (2011). · DOI
  29. Kang, S. M. et al. Identical epidermal growth factor receptor mutations in adenocarcinomatous and squamous cell carcinomatous components of adenosquamous carcinoma of the lung. Cancer 109, 581–587 (2007). · DOI · Paper page
  30. Niho, S., Yokose, T., Kodama, T., Nishiwaki, Y. & Mukai, K. Clonal analysis of adenosquamous carcinoma of the lung. Jpn J. Cancer Res. 90, 1244–1247 (1999). · DOI
  31. Shiozawa, T. et al. Clinicopathological characteristics of EGFR mutated adenosquamous carcinoma of the lung. Pathol. Int. 63, 77–84 (2013). · DOI
  32. King, K. E. & Weinberg, W. C. p63: defining roles in morphogenesis, homeostasis, and neoplasia of the epidermis. Mol. Carcinog. 46, 716–724 (2007). · DOI
  33. Westfall, M. D. & Pietenpol, J. A. p63: Molecular complexity in development and cancer. Carcinogenesis 25, 857–864 (2004). · DOI · Paper page
  34. Tomlinson, V. et al. JNK phosphorylates Yes-associated protein (YAP) to regulate apoptosis. Cell Death Dis. 1, e29 (2010). · DOI · Paper page
  35. Chaffer, C. L. et al. Poised chromatin at the ZEB1 promoter enables breast cancer cell plasticity and enhances tumorigenicity. Cell 154, 61–74 (2013). · DOI · Paper page
  36. Barry, E. R. et al. Restriction of intestinal stem cell expansion and the regenerative response by YAP. Nature 493, 106–110 (2013). · DOI · Paper page
  37. Ehsanian, R. et al. YAP dysregulation by phosphorylation or DeltaNp63-mediated gene repression promotes proliferation, survival and migration in head and neck cancer subsets. Oncogene 29, 6160–6171 (2010). · DOI · Paper page
  38. Yuan, M. et al. Yes-associated protein (YAP) functions as a tumor suppressor in breast. Cell. Death. Differ. 15, 1752–1759 (2008). · DOI · Paper page
  39. Zhang, Y. et al. Rapid increase of serum neuron specific enolase level and tachyphylaxis of EGFR-tyrosine kinase inhibitor indicate small cell lung cancer transformation from EGFR positive lung adenocarcinoma? Lung Cancer 81, 302–305 (2013). · DOI

Cited by

See all 123

Metadata

Authors
Gao, Y., Zhang, W., Han, X., Li, F., Wang, X., Wang, R., Fang, Z., Tong, X., Yao, S., Li, F., Feng, Y., Sun, Y., Hou, Y., Yang, Z., Guan, K., Chen, H., Zhang, L., & Ji, H.
Venue
Nature Communications
Published
2014-08-13
Volume
5
Issue
1
Pages
4629-4629
ISSN
2041-1723 (ISSN-L)
OpenAlex
W1980243795
Cited by
123
References
10
FWCI
5.80
Type
journal article
Language
en
Update notices
erratum (2015-02-27)
Open access
bronze
Licence

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.